1. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
- Author
-
Kent Y. Feng, MD, Rahul S. Loungani, MD, Vishal N. Rao, MD, MPH, Chetan B. Patel, MD, Michel G. Khouri, MD, G. Michael Felker, MD, MHS, and Adam D. DeVore, MD, MHS
- Subjects
amyloidosis ,biomarkers ,cardiac magnetic resonance ,cardiomyopathy ,echocardiography ,nuclear imaging ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
- Published
- 2019
- Full Text
- View/download PDF